CLINICAL TRIALS, STUDIES, REGISTRIES, DATA
1 min.Read

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

RhoVac AB, a Swedish cancer immunotherapy company, announces today, April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated today as the latest addition to US trial centres in RhoVac’s clinical phase IIb study, “BRaVac”, in prostate cancer.

Mount Sinai Hospital, founded in 1852, is one of the oldest and largest teaching hospitals in the United States, and it is widely recognised and one of the leading hospitals in the US, and indeed in the world, and as such RhoVac is extremely proud to declare its participation in the BRaVac trial.

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac’s Fast Track Designation. Immediately after the news on the Fast Track Designation was made public, Mount Sinai contacted RhoVac via its Scientific Advisory Board member, Professor Per-Anders Abrahamsson, who brokered the connection to RhoVac management. It is an honour for RhoVac, and a recognition of the potential of its drug candidate, that such a world leading hospital spontaneously seeks to join its clinical trial.

The site initiation visit is held, today, April 21st , and the study will be supervised at Mount Sinai by Professor Ash Tewari. In the trial, RhoVac’s drug candidate, RV001, will be used in prostate cancer patients that have previously had a prostatectomy or definitive radiation therapy, but that now have suffered a “Biochemical Recurrence” (rising PSA) but who still have not developed detectable metastases. The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for development.

RhoVac CEO, Anders Månsson, comments: “I was of course delighted when I learned that Mount Sinai wanted to join our study. I regard this as yet another example of the recognition that the Fast Track Designation has brought us already, and I am happy that we could get started so quickly. I wish Mount Sinai welcome on board the trial team, and I look forward to our collaboration”.

SourceRhoVac

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

0
Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

0
Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

0
Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

0
The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

0
“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device news and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York
United States
Phone Number: 1.561.316.3330